Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous methylnaltrexone for opioid-induced constipation in nonmalignant pain
2008-005961-77Phase 3Completed
- Sponsor
- Wyeth
- Start
- Feb 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in opioid-induced constipation (OIC) and constipation comparing Methylnaltrexone bromide 12 mg SC with Placebo SC (2 arms). Primary endpoints: Coprimary efficacy endpoints (unspecified) and Safety and tolerability. Started Feb 2009; status: completed.
02
Drugs
methylnaltrexone
03
Conditions
opioid-induced constipation (OIC)constipation
Beyond the preview
Go deeper on 2008-005961-77.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-005961-77.